You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 144 No. 10, October 1990 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (21)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Diurnal Variation in the Pharmacokinetics and Myelotoxicity of Mercaptopurine in Children With Acute Lymphocytic Leukemia

Gideon Koren, MD; Anne Marie Langevin, MD; Nancy Olivieri, MD; Ester Giesbrecht, MSc; Alvin Zipursky, MD; Mark Greenberg, MD

Am J Dis Child. 1990;144(10):1135-1137.


Abstract



• During their maintenance therapy, children with acute lymphoblastic leukemia are treated with a daily dose of mercaptopurine for several years. A recent retrospective analysis has suggested that administration of the drug in the evening results in a better prognosis. We compared the disposition pharmacokinetics of mercaptopurine administered in the morning vs in the evening in 13 children with acute lymphoblastic leukemia. Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 ±142 minutes vs 176 ± 22 minutes, mean ± SEM). The area under the concentration-time curve (AUC0-{infty}) was significantly larger in the evening (24713±3536 ng/mL per minute vs 17120±1474 ng/mL per minute). These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 mln.–{propto} 7724 ± 2955 ng/mL per minute in the evening vs 2597 ± 712 ng/mL per minute during the day). In a second study, 12 children with acute lymphoblastic leukemia receiving mercaptopurine in the morning had their medication administration switched to the evening. Within 2 weeks there was a sharp fall in peripheral white blood cell counts in all patients (from 4.1 109/L to 2.2 - 109/L) mainly due to a drop in polymorphonuclear lymphocytes (from 2.78x109/L to 1.05x109/L). We conclude that the diurnal variations of mercaptopurine disposition result in clinically important myelotoxicity of the drug.

(AJDC. 1990;144:1135-1137)



Author Affiliations



From the Divisions of Clinical Pharmacology (Dr Koren) and Hematology-Oncology (Drs Langevin, Olivieri, Zipursky, and Greenberg), Department of Pediatrics, the Department of Biochemistry (Ms Giesbrecht), and The Research Institute, The Hospital for Sick Children, Toronto, Departments of Pediatrics (Drs Koren, Olivieri, Zipursky, and Greenberg) and Pharmacology (Dr Koren), The University of Toronto, Canada.


Footnotes



Accepted for publication January 20, 1990.

Reprint requests to Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1x8 (Dr Koren).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.